Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus

A Corrigendum to this article was published on 01 January 2007

This article has been updated


The functions of 2-arachidonoylglycerol (2-AG), the most abundant endocannabinoid found in the brain, remain largely unknown. Here we show that two previously unknown inhibitors of monoacylglycerol lipase, a presynaptic enzyme that hydrolyzes 2-AG, increase 2-AG levels and enhance retrograde signaling from pyramidal neurons to GABAergic terminals in the hippocampus. These results establish a role for 2-AG in synaptic plasticity and point to monoacylglycerol lipase as a possible drug target.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: URB754 is a potent MGL inhibitor.
Figure 2: Inhibition of MGL, but not FAAH, activity prolongs DSI in CA1 pyramidal cells.

Change history

  • 12 December 2006

    Our paper identified 6-methyl-2-p-tolylaminobenzo[d]oxazin-4-one (URB754; Specs) as a monoacylglycerol lipase (MGL) inhibitor that enhances hippocampal depolarization-induced suppression of inhibition (DSI). However, in subsequent tests of non-commercial URB754, we failed to replicate these results, suggesting that a bioactive impurity was present in the commercial material. We have identified this impurity as bis(methylthio)mercurane (Supplementary Results online). Because this compound interacts with multiple targets, we tested another MGL inhibitor, methylarachidonylfluorophosphonate (MAFP), which prolonged DSI (Fig. 1), confirming that monoacylglycerol lipase contributes to the termination of DSI, as others have reported1. Another generation of endocannabinoid metabolism inhibitors is needed to test this hypothesis further.


  1. 1

    Freund, T.F., Katona, I. & Piomelli, D. Physiol. Rev. 83, 1017–1066 (2003).

    CAS  Article  Google Scholar 

  2. 2

    Wilson, R.I. & Nicoll, R.A. Nature 410, 588–592 (2001).

    CAS  Article  Google Scholar 

  3. 3

    Ohno-Shosaku, T., Maejima, T. & Kano, M. Neuron 29, 729–738 (2001).

    CAS  Article  Google Scholar 

  4. 4

    Wilson, R.I., Kunos, G. & Nicoll, R.A. Neuron 31, 453–462 (2001).

    CAS  Article  Google Scholar 

  5. 5

    Piomelli, D. Nat. Rev. Neurosci. 4, 873–884 (2003).

    CAS  Article  Google Scholar 

  6. 6

    Cravatt, B.F. et al. Nature 384, 83–87 (1996).

    CAS  Article  Google Scholar 

  7. 7

    Dinh, T.P. et al. Proc. Natl. Acad. Sci. USA 99, 10819–10824 (2002).

    CAS  Article  Google Scholar 

  8. 8

    Kim, J. & Alger, B.E. Nat. Neurosci. 7, 697–698 (2004).

    CAS  Article  Google Scholar 

  9. 9

    Porter, A.C. et al. J. Pharmacol. Exp. Ther. 301, 1020–1024 (2002).

    CAS  Article  Google Scholar 

  10. 10

    Huang, C.C., Chen, Y.L., Lo, S.W. & Hsu, K.S. Mol. Pharmacol. 61, 578–585 (2002).

    CAS  Article  Google Scholar 

  11. 11

    Hohmann, A.G. et al. Nature 435, 1108–1112 (2005).

    CAS  Article  Google Scholar 

  12. 12

    Kathuria, S. et al. Nat. Med. 9, 76–81 (2003).

    CAS  Article  Google Scholar 

  13. 13

    Krantz, A. et al. J. Med. Chem. 33, 464–479 (1990).

    CAS  Article  Google Scholar 

  14. 14

    Hodson, H.F. et al. International patent application PCT WO 00/40247 (2000).

Download references


We thank N. Hájos for valuable comments and J. Kim for help with cultures. This research was supported by grants from the US National Institute on Drug Abuse and the University of California Discovery Program (D.P.); from Ministero Istruzione Università e Ricerca and University of Urbino 'Carlo Bo' and University of Parma (G.T. and M.M.); and from the Howard Hughes Medical Institute, US National Institutes of Health, European Union Framework Programme 6 and Országos Tudományos Kutatási Alapprogramok (T.F.F).

Author information



Corresponding authors

Correspondence to Tamás F Freund or Daniele Piomelli.

Ethics declarations

Competing interests

The authors declare competing financial interests: a patent was filed on behalf of D.P., A.D., A.T., M.M. and G.T. by the University of California, Irvine; the University of Urbino and the University of Parma.

Supplementary information

Supplementary Fig. 1

The effect of URB602 on DSI is mediated by CB1 receptors. (PDF 184 kb)

Supplementary Fig. 2

URB602 does not affect depolarization-evoked Ca2+ transients in hippocampal CA1 pyramidal neurons. (PDF 635 kb)

Supplementary Fig. 3

URB754 and URB602 do not inhibit FAAH activity in rat forebrain slice cultures. (PDF 562 kb)

Supplementary Fig. 4

Effects of a high concentration of URB754 (3 μM) on hippocampal DSI. (PDF 1137 kb)

Supplementary Table 1

Kinetic analysis of the effects of URB754 on the activity of recombinant rat brain MGL expressed in HeLa cells. (PDF 38 kb)

Supplementary Methods (PDF 128 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Makara, J., Mor, M., Fegley, D. et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8, 1139–1141 (2005).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing